NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Myelofibrosis (splenomegaly, symptoms) - ruxolitinib - NICE TAG TA289

Myelofibrosis (splenomegaly, symptoms) - ruxolitinib - NICE TAG TA289

1.1 Ruxolitinib is not recommended within its marketing authorisation, that is, for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

1.2 People currently receiving ruxolitinib should be able to continue treatment until they and their clinician consider it appropriate to stop.

 

https://www.nice.org.uk/guidance/TA289

Site by Devopa
© Copyright 2019 NHS. All rights reserved.